Funding for this research was provided by:
Cipla Ltd., India
Received: 23 March 2021
Accepted: 22 December 2021
First Online: 4 January 2022
: There was no need for administrative permissions, since it was mandatory for all hospitals and clinics that administered remdesivir in COVID-19 patients to provide data (through an active surveillance form) thus, obtaining ethical approval and informed consent was not required. As a part of regulatory approval, Cipla Ltd has to provide the data report to Central Drugs Standard Control Organisation (CDSCO) periodically. The data were anonymised before its use.
: Not applicable.
: All the authors are permanent employees of Cipla Ltd., India who had a role in the study. The study was funded by Cipla Ltd., India, and was the provider of the drug.